Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

(2012) L. Alinari et al.   CLINICAL CANCER RESEARCH

SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells

(2012) Yao Guo et al.   Journal of Hematology & Oncology

MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status

(2012) Isabella Faraoni et al.   Journal of Hematology & Oncology

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155

(2012) D W Lee et al.   ONCOGENE

Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography–Tandem Mass Spectrometry

(2011) U. V. R. Vijaya Saradhi et al.   AAPS Journal

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

(2011) Shinichiro Takahashi   Journal of Hematology & Oncology

The Relevance of Higher Plants in Lead Compound Discovery Programs

(2011) A. Douglas Kinghorn et al.   JOURNAL OF NATURAL PRODUCTS

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) S. P. Whitman et al.   BLOOD

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Bench to Bedside Targeting of FLT3 in Acute Leukemia

(2010) Keith W. Pratz et al.   CURRENT DRUG TARGETS

NF-κB Down-regulates Expression of the B-lymphoma Marker CD10 through a miR-155/PU.1 Pathway

(2010) Ryan C. Thompson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Drug resistance in mutant FLT3-positive AML

(2010) E Weisberg et al.   ONCOGENE

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

(2009) David M. Lucas et al.   BLOOD

Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia

(2009) S. Meshinchi et al.   CLINICAL CANCER RESEARCH

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML

(2009) Ellen Weisberg et al.   DRUG RESISTANCE UPDATES

Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells

(2009) Regina Cencic et al.   LEUKEMIA RESEARCH

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One

Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

(2008) Jennifer Grosjean-Raillard et al.   APOPTOSIS

MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia

(2008) R. Garzon et al.   BLOOD

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD

MicroRNAs in normal and malignant hematopoiesis

(2008) Ramiro Garzon et al.   CURRENT OPINION IN HEMATOLOGY

Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder

(2008) Ryan M. O'Connell et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia

(2008) Soo-Mee Bang et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin

(2008) R. Garzon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA